

Irit Carmi Levy Company name-----Aummune----- \* Website-----  
https://aummune.com/----- \* CEO name-----Irit Carmi Levy\* Select a CATEGORY:

Biotech/Pharma \* • Evolving trends in cancer therapeutics

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Aummune is a clinical stage oncology company pioneering a unique approach, coupling immunotherapy with patient-tailored platform. A Phase 1 study with our lead asset is showing encouraging results. To the extent that the clinical work continues to show promise, this could be one of the most exciting ventures in the oncology space.

o Core Technology What is the technology, its uniqueness, and its value proposition? Aummune has developed a cutting-edge, proprietary platform, for the identification of a novel and unique drug per patient. This individualized drug is selected based on its ability to induce a substantial tumor cell death, on the patient's own cancerous cells while leaving healthy normal cells intact.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Aummune's therapeutic product is a unique individualized immunotherapy. Its customized moiety is designed to selectively bind unique targets on the surface of tumor cells to induce tumor cell death, while the second moiety is designed to activate immune cells from the adaptive and innate compartments- both. Aummune's technology aims to disrupt both growing markets of personalized therapies and immunotherapeutic.

o Business Strategy Briefly describe how the company will apply its core technology, generate shortterm and long-term revenues. Aummune's oncology therapies will be provided as an end-to-end service, from tissue sampling to computation, design, testing, and GMP production of the therapeutic DNA oligo molecules, to safe delivery of the therapeutic dose to the patient's hospital. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans A

Phase 2 trial is planned to be initiated in the second half of 2024 !